{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:38:22Z","timestamp":1782538702093,"version":"3.54.5"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Trial on Development of New Drugs and Medical Devices"},{"name":"Japanese Ministry of Health, Labor and Welfare"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15lk0103004"],"award-info":[{"award-number":["JP15lk0103004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To predict the efficacy of IL-6 inhibition in patients with Still\u2019s disease by analysing inflammatory cytokine profiles before and during an IL-6 receptor inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a subanalysis of the 52-week, randomized, double-blind, placebo-controlled trial of tocilizumab, an IL-6 receptor inhibitor, in patients with Still\u2019s disease. Multiple serum cytokine levels were measured regularly, and their pattern and profiles were analysed based on the response to tocilizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 26 patients (13 in the tocilizumab group and 13 in the placebo group) were enrolled. Before tocilizumab treatment, IL-6 levels were correlated with DAS with 28 joints (r = 0.67, P &amp;lt; 0.01), and IL-1\u03b2, IL-6 and IL-18 levels tended to be correlated with systemic feature score (r\u2009=\u20090.33, P = 0.09; r\u2009=\u20090.38, P = 0.05; r\u2009=\u20090.40, P = 0.04, respectively). IL-6 and IL-6 receptor levels were significantly elevated after tocilizumab initiation, while the other cytokines showed no significant difference compared with placebo. Baseline levels of IFN-\u03b3 and IL-1\u03b2 were significantly higher in non-responders compared with responders (28.49 vs 5.65\u2009pg\/ml, P = 0.03; 0.26 vs 0.04\u2009pg\/ml, P = 0.048), and IFN-\u03b3 and IL-18 levels at week 52 remained high in non-responders (15.56 vs 7.03\u2009pg\/ml, P = 0.02; 5924 vs 392\u2009pg\/ml, P = 0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effect of tocilizumab is limited to the IL-6 signalling pathway in Still\u2019s disease. Patients who did not respond to tocilizumab exhibited distinct cytokine profiles that pivot the IFN-\u03b3 axis. These findings highlight the role of IL-6 inhibition in Still\u2019s disease and shed light on its personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>UMIN Clinical Trials Registry; UMIN000012987.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf254","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:06:45Z","timestamp":1747818405000},"page":"5948-5957","source":"Crossref","is-referenced-by-count":6,"title":["Serum cytokine levels towards precision medicine in Still\u2019s disease: a subanalysis of a randomized controlled trial of tocilizumab"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu,","place":["Japan"]},{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5824","authenticated-orcid":false,"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Graduate School of Medicine , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-4648","authenticated-orcid":false,"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-5142","authenticated-orcid":false,"given":"Hyota","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center for Autoimmune Diseases, National Hospital Organization, Osaka Minami Medical Center , Osaka,","place":["Japan"]},{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5442-7034","authenticated-orcid":false,"given":"Takayuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Faculty of Data Science, Kyoto Women\u2019s University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]},{"name":"Saitama Medical University , Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"2025110820502111900_keaf254-B1","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2025110820502111900_keaf254-B2","first-page":"ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease","volume":"14","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025110820502111900_keaf254-B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025110820502111900_keaf254-B4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still\u2019s disease. Association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820502111900_keaf254-B5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult Still\u2019s disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025110820502111900_keaf254-B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2025110820502111900_keaf254-B7","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/rheumatology\/kead461","article-title":"Management of adult-onset Still\u2019s disease: evidence- and consensus-based recommendations by experts","volume":"63","author":"Leavis","year":"2024","journal-title":"Rheumatology"},{"key":"2025110820502111900_keaf254-B8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820502111900_keaf254-B9","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/1756-185X.14848","article-title":"Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still\u2019s disease: an analysis of a Japanese claims database","volume":"26","author":"Kaneko","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2025110820502111900_keaf254-B10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025110820502111900_keaf254-B11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still\u2019s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025110820502111900_keaf254-B12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025110820502111900_keaf254-B13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025110820502111900_keaf254-B14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025110820502111900_keaf254-B15","first-page":"396","article-title":"Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still\u2019s disease","volume":"25","author":"Hoshino","year":"1998","journal-title":"J Rheumatol"},{"key":"2025110820502111900_keaf254-B16","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"2025110820502111900_keaf254-B17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"key":"2025110820502111900_keaf254-B18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22194","article-title":"Clinical manifestations of adult-onset Still\u2019s disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18: characteristics of AOSD with severe arthritis","volume":"66","author":"Ichida","year":"2014","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2025110820502111900_keaf254-B19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/mr\/roab004","article-title":"Interluekin-6 inhibitors for the treatment of adult-onset Still\u2019s disease","volume":"32","author":"Kaneko","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025110820502111900_keaf254-B20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","article-title":"Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis","volume":"40","author":"Shimamoto","year":"2013","journal-title":"J Rheumatol"},{"key":"2025110820502111900_keaf254-B21","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"2025110820502111900_keaf254-B22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","article-title":"Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study","volume":"36","author":"Okano","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025110820502111900_keaf254-B23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10067-021-05921-2","article-title":"The effectiveness of tocilizumab in treating refractory adult-onset Still\u2019s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response","volume":"41","author":"Tang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025110820502111900_keaf254-B24","first-page":"2100","article-title":"Markedly elevated serum IL-6 levels predict relapse within six months of treatment initiation in Still\u2019s disease","volume":"42","author":"Oka","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025110820502111900_keaf254-B25","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2169\/internalmedicine.50.4771","article-title":"Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset still\u2019s disease","volume":"50","author":"Yoshida","year":"2011","journal-title":"Intern Med"},{"key":"2025110820502111900_keaf254-B26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"2025110820502111900_keaf254-B27","doi-asserted-by":"publisher","first-page":"e003419","DOI":"10.1136\/rmdopen-2023-003419","article-title":"Derivation and validation of four patient clusters in Still\u2019s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry","volume":"9","author":"Ruscitti","year":"2023","journal-title":"RMD Open"},{"key":"2025110820502111900_keaf254-B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025110820502111900_keaf254-B29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"key":"2025110820502111900_keaf254-B30","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still\u2019s disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820502111900_keaf254-B31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025110820502111900_keaf254-B32","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/annrheumdis-2018-214496","article-title":"Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025110820502111900_keaf254-B33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","article-title":"Recent advances and evolving concepts in Still\u2019s disease","volume":"20","author":"Ruscitti","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025110820502111900_keaf254-B34","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.3390\/jcm10194400","article-title":"Distinct effects of interleukin-1\u03b2 inhibition upon cytokine profile in patients with adult-onset Still\u2019s disease and active articular manifestation responding to canakinumab","volume":"10","author":"Ghannam","year":"2021","journal-title":"J Clin Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf254\/63474882\/keaf254.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5948\/63474882\/keaf254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5948\/63474882\/keaf254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:50:33Z","timestamp":1762653033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5948\/8160776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,15]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf254","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,15]]}}}